Every Form 4 that 10x Genomics, Inc. (TXG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TXG filings page.
10x Genomics, Inc. director Suliman Shehnaaz sold 5,723 shares of Class A Common Stock in five reported transactions on September 22, 2026. The reported weighted average sale prices were $78.1959, $79.5114, $80.8164, $81.6699 and $82.2768 per share. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.
10x Genomics, Inc. (TXG) Chief Executive Officer Serge Saxonov reported five direct sales totaling 25,000 Class A common shares on September 22, 2026. The reported weighted-average sale prices were $78.2284 for 1,000 shares, $79.6195 for 2,000, $80.9033 for 9,300, $81.8254 for 9,900, and $82.3650 for 2,800 shares. The sales were made under a Rule 10b5-1 trading plan adopted November 29, 2025.
10x Genomics, Inc. (TXG) reported that its Chief Financial Officer, Adam Taich, sold a total of 46,388 shares of Class A Common Stock on September 9, 2026 in three open-market transactions at weighted average prices ranging from about $63.68 to $65.26, under a Rule 10b5-1 trading plan adopted on June 10, 2026.
10x Genomics, Inc. (TXG) director John R. Stuelpnagel reported selling a total of 20,000 shares of Class A common stock on September 3, 2026 in open-market transactions. The shares were sold in three blocks at weighted average prices around $60.66, $62.11, and $62.61, each executed across multiple trade prices, and no Rule 10b5-1 trading plan is reported.
10x Genomics, Inc. (TXG) reports that Chief Executive Officer and director Serge Saxonov made a bona fide gift of 100 shares of Class A Common Stock on September 1, 2026, at a reported price of $0.00 per share. Following the gift, he held 1,075,249 Class A shares directly, and also had indirect ownership interests as trustee of the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust. No Rule 10b5-1 trading plan is reported for this transaction.
10x Genomics, Inc. (TXG) reported that its Chief Executive Officer, Serge Saxonov, sold a total of 10,486 shares of Class A Common Stock on August 26, 2026. The sales, executed as open-market or private transactions, were carried out pursuant to a Rule 10b5-1 trading plan adopted on November 29, 2025 and occurred in multiple trades with weighted average prices between approximately $62.53 and $64.99. The filing also notes indirect holdings of Class A shares in three trusts—the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust—for which Saxonov serves as trustee.
10x Genomics, Inc. (TXG) reported an insider transaction by Chief Executive Officer and director Serge Saxonov. On 2026-08-24, he sold 18,545 shares of Class A Common Stock at a weighted average price of $63.0237 per share in open-market trades, solely to cover tax withholding obligations arising from the vesting of restricted stock units. After this sale, he directly held 1,085,835 shares of Class A Common Stock and also had indirect holdings through three trusts for which he serves as trustee.
10x Genomics, Inc. (TXG) reported that its Chief Financial Officer, Adam Taich, sold 17,166 shares of Class A common stock on 2026-08-24. The filing states the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The weighted average sale price was $63.023 per share, with individual trades executed between $63.0088 and $63.73. After these sales, Taich directly held 362,732 shares of Class A common stock.
10x Genomics, Inc. (TXG) reported that Benjamin J. Hindson, its President and Chief Scientific Officer and a director, sold 13,818 shares of Class A common stock on August 24, 2026. The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and Hindson held 488,182 shares directly after the transaction. The sale price reflected a weighted average of $63.0236 per share from multiple trades between $63.0088 and $63.78.
10x Genomics, Inc. (TXG) director Shehnaaz Suliman reported two open-market sales of Class A Common Stock on August 24, 2026. The transactions totaled 2,207 shares, consisting of 561 shares at a weighted average price of $62.7259 and 1,646 shares at a weighted average price of $63.9664. Both sales were executed under a Rule 10b5-1 trading plan adopted on March 13, 2026, and each price reflects a weighted average across multiple trades within stated price ranges.
10x Genomics, Inc. (TXG) reported that Chief Executive Officer and director Serge Saxonov made a bona fide gift of 4,000 shares of Class A Common Stock on August 20, 2026. After this gift, he directly holds 1,104,380 Class A shares and also reports indirect holdings in several family trusts for which he serves as trustee.
10x Genomics, Inc. director Sarah A. Teichmann reported two open-market sales of Class A Common Stock of TXG. On August 13, 2026 she sold 5,278 shares at $57.29 per share, and on August 14, 2026 she sold 2,273 shares at $57.15 per share, for total reported sales of 7,551 shares. Both transactions were effected pursuant to her Rule 10b5-1 trading plan adopted on May 14, 2026.
10x Genomics, Inc. director John R. Stuelpnagel reported selling a total of 20,000 shares of Class A Common Stock on August 11, 2026. The sales consisted of 17,000 shares at a weighted average price of $57.5812 per share, executed in multiple trades between $57.50 and $58.1525, and 3,000 shares at $58.7250 per share in a separate transaction.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported open-market sales of 30,000 shares of Class A common stock on June 22, 2026. The sales occurred in multiple trades at weighted average prices around $33–$36 per share, as detailed by price ranges in the filing.
The transactions were made under Saxonov’s pre-arranged Rule 10b5-1 trading plan, adopted on November 29, 2025. After these sales, he holds approximately 1,108,380 shares directly, plus additional indirect holdings through the Andromeda Trust, the Y/S Descendants’ Trust, and the Y/S Pot Trust.
10x Genomics, Inc. director Shehnaaz Suliman reported selling a total of 5,723 shares of Class A Common Stock in open-market transactions. The sales occurred on June 16, 2026 at weighted average prices of $32.5890 and $33.2738 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026.
Teichmann Sarah A. reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Sarah A. Teichmann received an equity award of 8,829 restricted stock units (RSUs) of Class A Common Stock. The award was granted at no cash cost per share and increased her direct holdings to 35,609 shares.
Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. One quarter of the RSUs will vest on each quarterly anniversary starting from May 21, 2026, as long as she continues as a service provider through each vesting date.
SULIMAN SHEHNAAZ reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Shehnaaz Suliman received an equity award of 8,829 restricted stock units (RSUs) of Class A Common Stock. The grant has no cash purchase price and increases her direct holdings to 37,445 shares. The RSUs vest in four equal quarterly installments starting on May 21, 2026, as long as she continues as a service provider.
STUELPNAGEL JOHN R reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics, Inc. director John R. Stuelpnagel received an equity award of 8,829 restricted stock units (RSUs), each representing one future share of Class A Common Stock upon vesting. The RSUs vest in four equal installments on each quarterly anniversary of May 21, 2026, as long as he continues as a service provider. After this grant, he holds 368,436 shares of Class A Common Stock directly.
Popovits Kimberly J reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Kimberly J. Popovits received an equity award in the form of restricted stock units. She was granted 8,829 RSUs, each representing one share of Class A Common Stock at no cash cost, bringing her direct holdings to 37,445 shares. One quarter of the RSUs will vest on each quarterly anniversary starting from May 21, 2026, as long as she continues as a service provider on those dates.
MATEO ALAN reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics, Inc. director Alan Mateo reported an equity compensation grant in the form of 8,829 restricted stock units (RSUs) for Class A Common Stock. Each RSU represents one share upon vesting. The award vests in four equal quarterly installments beginning on May 21, 2026, contingent on continued service.
Following this grant, Mateo directly holds 85,877 shares of Class A Common Stock, reflecting his updated equity stake in the company.
Kosaraju Sridhar reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Sridhar Kosaraju reported a stock-based compensation award. He received a grant of 8,829 shares of Class A Common Stock as restricted stock units (RSUs) at no cash cost. After this grant, he holds 65,278 shares directly.
The RSUs vest in four equal installments on each quarterly anniversary starting on May 21, 2026, as long as he continues as a service provider through each vesting date. The filing also shows 3,000 Class A shares held indirectly through the Kosaraju Family Trust, where he serves as trustee.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported open‑market sales of Class A Common Stock primarily tied to tax withholding on equity awards. On May 26, 2026, he sold 10,718 shares at a weighted average price of $24.7092 per share. On May 22, 2026, he sold 18,175 shares at a weighted average price of $24.4415 per share. A footnote states the shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units and that the transactions were effected under his Rule 10b5‑1 trading plan adopted on November 29, 2025. After these transactions, Saxonov directly holds 1,138,380 shares, with additional indirect holdings through the Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust, for which he serves as trustee.
10x Genomics, Inc. director and officer Benjamin J. Hindson reported a small share disposition tied to tax obligations. On May 22, 2026, he sold 11,595 shares of Class A Common Stock at $24.4415 per share to cover tax withholding from vesting restricted stock units. Following this transaction, he still directly holds 502,000 shares, indicating the move is a routine, compensation-related tax event rather than a large discretionary sale.
10x Genomics, Inc. Chief Financial Officer Adam Taich reported a sale of company stock primarily to satisfy taxes from equity compensation. On May 22, 2026, he sold 15,098 shares of Class A Common Stock at an average price of $24.4415 per share. According to the footnote, the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, making this a routine, compensation-driven transaction rather than a discretionary portfolio move. After the sale, Taich directly holds 379,898 shares of 10x Genomics Class A Common Stock.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov sold 5,000 shares of Class A Common Stock in an open-market transaction at a weighted average price of $24.5568 per share on April 14, 2026. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2025, indicating it was scheduled in advance.
Following the sale, Saxonov directly holds 1,167,273 shares of Class A Common Stock. He also has indirect holdings through trusts where he serves as trustee, including 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 71,644 shares in the Y/S Pot Trust.
10x Genomics, Inc. CEO Serge Saxonov reported open‑market sales of 15,000 shares of Class A Common Stock. He sold 10,000 shares on March 23, 2026 at a weighted average price of $19.1297 per share and 5,000 shares on March 24, 2026 at a weighted average price of $19.5223 per share.
The filing states these transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 29, 2025. After the sales, he directly holds 1,172,273 shares of Class A Common Stock and also has significant additional indirect and Class B holdings held through various trusts where he serves as trustee, with each Class B share convertible into one Class A share.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported planned share sales and a gift of stock. On March 2, 2026, he sold a total of 16,152 shares of Class A common stock in open-market transactions at weighted average prices of $22.6690 and $23.1781, effected under a Rule 10b5-1 trading plan adopted on November 29, 2025. On March 3, 2026, he made a bona fide gift of 2,750 shares at no consideration. After these transactions, he directly held 1,200,917 shares of Class A common stock, and also had indirect holdings of 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust, for which he serves as trustee.
10x Genomics, Inc. reported that Chief Executive Officer Serge Saxonov acquired an equity award in the form of restricted stock units covering 157,895 shares of Class A Common Stock at a stated price of $0.00 per share on February 26, 2026.
Each RSU represents a right to receive one share of Class A Common Stock upon vesting. According to the terms, 1/12 of the RSUs vest on each quarterly anniversary starting from February 21, 2026, as long as he continues as a service provider on each vesting date.
The filing also lists indirect holdings of Class A Common Stock held by the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust, for which Saxonov serves as trustee, totaling separate positions of 27, 213,250, and 58,000 shares respectively.
Hindson Benjamin J. reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics, Inc. reported that director and officer Benjamin J. Hindson received a grant of 88,816 restricted stock units (RSUs) linked to its Class A Common Stock at a stated price of $0.00 per share. Each RSU represents a right to receive one share upon vesting.
According to the award terms, 1/12 of the RSUs will vest on each quarterly anniversary starting on February 21, 2026, as long as Hindson continues as a service provider through each vesting date. After this grant, his directly held Class A Common Stock, including RSUs, totals 513,595 shares.
Taich Adam reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics Chief Financial Officer Adam Taich received an equity award of 106,579 shares of Class A Common Stock in the form of restricted stock units (RSUs). The award was granted at no cash cost per share and increases his directly held beneficial ownership to 394,996 shares.
The RSUs vest over time, with 1/12 of the units vesting on each quarterly anniversary starting from February 21, 2026, as long as he continues as a service provider through each vesting date. This structure is designed to align his compensation with the company’s long-term performance and retention.
10x Genomics, Inc. director Sarah A. Teichmann reported an open-market sale of 7,579 shares of Class A Common Stock at $19.41 per share. After this transaction, she directly holds 26,780 shares. The sale was executed under her pre-arranged Rule 10b5-1 trading plan.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported an open-market sale of 9,632 shares of Class A common stock on February 23, 2026 at an average price of $18.5764 per share. The shares were sold to cover tax withholding obligations related to vesting restricted stock units.
After this transaction, Saxonov directly held 1,061,924 Class A shares. In addition, indirect holdings as trustee included 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust.
10x Genomics Chief Financial Officer Adam Taich reported an open-market sale of 8,968 shares of Class A Common Stock. The transaction took place on February 23, 2026 at an average price of $18.5764 per share, and was conducted to cover tax withholding obligations related to vesting restricted stock units.
After this transaction, Taich directly owned 288,417 shares of 10x Genomics Class A Common Stock.
10x Genomics, Inc. director and officer Benjamin J. Hindson reported an open-market sale of 7,826 shares of Class A common stock at an average price of $18.5764 per share. According to the filing, the shares were sold to cover tax withholding obligations from vesting restricted stock units. After this transaction, Hindson directly owns 424,779 shares.
10x Genomics, Inc. reported that Chief Executive Officer and director Serge Saxonov exercised stock options on January 5, 2026 to acquire 50,000 shares of Class A common stock at $1.20 per share. These shares now form part of his directly held stake of 1,071,556 Class A shares following the transaction.
The filing shows two option exercises, covering 17,463 and 32,537 underlying shares, from fully vested options expiring on October 18, 2027, leaving 173,600 stock options outstanding. In addition to his direct holdings, Saxonov is reported as trustee for three trusts that hold 27, 213,250 and 58,000 Class A shares, respectively.
10x Genomics, Inc. (TXG) reported an insider stock transaction by its Chief Financial Officer. On 11/24/2025, the CFO disposed of 11,888 shares of Class A common stock in a sale transaction at a price of $18.9983 per share. After this transaction, the officer beneficially owns 297,385 shares of Class A common stock in direct ownership form.
The company notes that the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, meaning the transaction was connected to equity compensation rather than an open-market liquidation of a larger personal position.
10x Genomics, Inc. reported an insider stock transaction by a senior executive. On 11/24/2025, a reporting person who serves as both a director and as President and Chief Scientific Officer sold 8,283 shares of Class A common stock of 10x Genomics, Inc. (TXG) at a price of $18.9983 per share. According to the explanation provided, the shares were sold to cover tax withholding obligations that arose when restricted stock units vested, meaning the transaction was tied to equity compensation rather than a discretionary open-market sale.
After this transaction, the reporting person beneficially owned 432,605 shares of Class A common stock in direct form. The Form 4 was filed for a single reporting person and does not report any derivative securities activity.
10x Genomics, Inc. (TXG) Chief Executive Officer and Director Serge Saxonov reported a sale of Class A common stock in a Form 4 filing. On 11/24/2025, he sold 13,261 shares at an average price of $18.9983 per share in a transaction coded "S," which the notes explain was to cover tax withholding obligations from vesting restricted stock units.
After this transaction, Saxonov beneficially owns 1,021,556 Class A shares directly. He also reports indirect ownership of 27 shares through the Andromeda Trust, 213,250 shares through the Y/S Descendants' Trust, and 58,000 shares through the Y/S Pot Trust, where he serves as trustee.